Skip to content

TTRX TTRX Investing Cash Flow

Investing Cash Flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$428.9M-166%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$139M-6.9%
PTH
Pelthos Therapeutics Inc.PTHS
-$194K
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$72.12M+67.9%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-$11.33M-196%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$142.84M-394%

Other financials

Income statement

See full
Operating income-$1.2M-224%
Net income-$971.0K-196%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$11.2M+613%
Total debt$6.0M
Total equity$6.1M+647%
Total assets$18.6M

Cash flow

See full
Operating cash flow-$1.6M-448%

Valuation

See full
Market cap$217.45M-17.7%
Enterprise value$212.24M

Returns & leverage

See full
Return on equity-118.8%
Debt / equity
Current ratio2.2×

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TTRX's investing cash flow?
TTRX (TTRX) reported investing cash flow of -$12.23K in Q1 2026.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.